This is a temporary backup site for TRENDS MENA while our primary website is being restored following a regional disruption affecting Amazon Web Services cloud infrastructure in the GCC.

Search Site

ADNOC Distribution 2025 dividend $700m

The company had reported EBITDA of $1.17 bn in 2025.

Empower okays $119.1m H2 2025 dividend

The dividend is equivalent to 43.75% of paid-up capital.

Alujain widens 2025 loss

The increase in loss is due to impairment charges, weaker prices.

Masar 2025 net profit $262m

Higher land plot sales boost revenue and operating income.

Tasnee’s 2025 losses deepen

The petrochemicals' company's revenue also fell 17.7 percent.

Saudi Chemical, GlaxoSmithKline enter into $27m manufacturing deal

    • New partnership would help create more jobs for Saudis in the Kingdom’s pharmaceuticals sector

    • The partnership is in keeping with Saudi vision to diversify its economy away from oil

    Saudi Chemical Company Holding (SCCH) and GlaxoSmithKline have entered into a partnership to make pharmaceutical products in Saudi Arabia. SCCH unit AJA Pharmaceutical Industries have teamed up with GlaxoSmithKline Consumer Healthcare Saudi in a five-year production deal worth SR100 million ($27 million), the company said in a Saudi stock exchange filing on Thursday.

    Quoting SCCH Chief Executive Officer, Arab News reported that the new partnership would help create more jobs for Saudis in the Kingdom’s pharmaceuticals sector. “Our mission is to be the partner of choice,” said SCCH CEO Thamer Al-Muhid.

    Saudi Arabia aims to diversify its economy away from oil by adding more high value jobs at home and replacing imports with domestic manufacturing in key sectors such as pharmaceuticals.